NICE Recommends Eli Lilly’s Verzenios for Early Breast Cancer
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Verzenios (abemaciclib) for National Health Service (NHS) use in patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence after surgery.
The twice-daily oral drug works by inhibiting proteins in cancer cells. In a clinical study, participants given Verzenios along with hormone therapy improved the chances of their cancer not returning by more than 30 percent compared with those given hormone therapy alone.
Verzenios’ listed price is over $3,590 per 28-day cycle of 150 mg tablets. The negotiated price for NHS use was not disclosed.
June 21, 2022
